1. Home
  2. CME vs REGN Comparison

CME vs REGN Comparison

Compare CME & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CME Group Inc.

CME

CME Group Inc.

N/A

Current Price

$270.55

Market Cap

79.9B

Sector

Finance

ML Signal

N/A

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$826.79

Market Cap

68.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CME
REGN
Founded
1898
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.9B
68.8B
IPO Year
2002
1995

Fundamental Metrics

Financial Performance
Metric
CME
REGN
Price
$270.55
$826.79
Analyst Decision
Buy
Buy
Analyst Count
13
25
Target Price
$307.42
$830.16
AVG Volume (30 Days)
2.1M
762.4K
Earning Date
04-22-2026
04-29-2026
Dividend Yield
3.95%
0.55%
EPS Growth
15.41
8.19
EPS
6.06
18.95
Revenue
$6,520,600,000.00
$5,872,227,000.00
Revenue This Year
$10.08
$12.45
Revenue Next Year
$4.40
$10.13
P/E Ratio
$44.05
$44.37
Revenue Growth
6.37
20.82
52 Week Low
$218.31
$541.00
52 Week High
$329.16
$844.92

Technical Indicators

Market Signals
Indicator
CME
REGN
Relative Strength Index (RSI) 61.75 76.46
Support Level $262.27 $732.04
Resistance Level $279.39 N/A
Average True Range (ATR) 5.97 18.94
MACD 0.33 2.88
Stochastic Oscillator 88.53 83.92

Price Performance

Historical Comparison
CME
REGN

About CME CME Group Inc.

Based in Chicago, CME Group operates exchanges giving investors, suppliers, and businesses the ability to trade futures and derivatives based on interest rates, equity indexes, foreign currencies, energy, metals, and commodities. The Chicago Mercantile Exchange was founded in 1898 and in 2002 completed its IPO. Since then, CME Group has consolidated parts of the industry by merging with crosstown rival CBOT Holdings in 2007 before acquiring Nymex Holdings in 2008 and NEX in 2018. In addition, the company has a 27% stake in S&P Dow Jones Indexes, making the Chicago Mercantile Exchange the exclusive venue to trade and clear S&P futures contracts. Through CME's acquisition of NEX, it also expanded into cash foreign exchange, fixed-income trading, and collateral optimization.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Share on Social Networks: